Patents by Inventor Kathleen Cogan Farinas
Kathleen Cogan Farinas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11813196Abstract: An apparatus to treat a patient comprises a container to receive fluid of a device implanted in the eye. The fluid of the device can be analyzed to determine a component of the vitreous humor of the eye.Type: GrantFiled: August 14, 2019Date of Patent: November 14, 2023Assignee: ForSight Vision4, Inc.Inventors: Signe Erickson, Darren Doud, Eugene de Juan, Jr., Yair Alster, Cary J. Reich, Kathleen Cogan Farinas
-
Patent number: 11786396Abstract: Methods and apparatus provide a therapeutic fluid to devices implanted in the body, for example to containers of devices implanted in the eye of a patient. The methods and apparatus may comprise an injector to increase an amount of therapeutic agent injected into the device implanted in the eye, or a structure to receive the therapeutic fluid within the device implanted in the eye, or combinations thereof. The device implanted in the eye may comprise a reservoir chamber having a fluid with a density different than the therapeutic fluid, and the apparatus can be adapted to at least partially separate the implanted device fluid from therapeutic fluid within the reservoir chamber to increase and amount of therapeutic fluid placed in the reservoir chamber.Type: GrantFiled: April 17, 2019Date of Patent: October 17, 2023Assignee: ForSight Vision4, Inc.Inventors: Eugene de Juan, Jr., Yair Alster, Kathleen Cogan Farinas, K. Angela Macfarlane, Cary J. Reich, Randolph E. Campbell, Darren Doud, Signe Erickson, Mike Barrett, David Batten, Christina Skieller, Greg Stine
-
Patent number: 11679027Abstract: Methods and apparatus provide treatment with a first therapeutic agent and a second therapeutic agent for an extended time. The first therapeutic agent may comprise a VEGF inhibitor and the second therapeutic agent may comprise an antiinflammatory, such as a non-steroidal anti-inflammatory, for example a cyclooxygenase inhibitor. One or more of the first therapeutic agent or the second therapeutic agent can be injected into the eye, for example injected into a therapeutic device implanted into the eye to release the injected therapeutic agent for an extended time.Type: GrantFiled: March 4, 2020Date of Patent: June 20, 2023Assignee: ForSight Vision4, Inc.Inventors: Eugene de Juan, Jr., Yair Alster, Kathleen Cogan Farinas, Cary J. Reich, Randolph E. Campbell, K. Angela MacFarlane, Signe Erickson
-
Patent number: 11642310Abstract: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.Type: GrantFiled: April 7, 2020Date of Patent: May 9, 2023Assignee: ForSight Vision4, Inc.Inventors: Eugene de Juan, Jr., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, Hanson S. Gifford, III, K. Angela Macfarlane, Cary J. Reich, Michael Barrett, Randolph E. Campbell, Robert George, Douglas Sutton
-
Publication number: 20230072346Abstract: A therapeutic device for extended release drug delivery including a refillable reservoir configured to receive a therapeutic agent and having an outlet for delivery of the therapeutic agent to a patient from the reservoir over an extended period. A porous structure is coupled near the outlet of the reservoir, the porous structure formed of sintered material. A barrier layer is coupled to the reservoir on or adjacent a surface of the porous structure such that the therapeutic agent passes through both the porous structure and the barrier layer upon delivery from the reservoir through the outlet. The porous structure is tuned to deliver the therapeutic agent at a diffusion rate and the barrier layer is adapted to block passage of particles having an average particle size within an average particle size range that is outside an average particle size range blocked by the porous structure. Related methods and systems are provided.Type: ApplicationFiled: July 29, 2022Publication date: March 9, 2023Inventors: Randolph E. Campbell, Kevin W. Sacherman, Kathleen Cogan Farinas, Signe Erickson, Jeremy Boyette
-
Publication number: 20230000676Abstract: A device for injecting a therapeutic agent into an ocular implant at least partially implanted in an eye including an injection lumen providing a pathway for injecting the therapeutic agent into the implant; an outlet lumen providing a pathway for pre-existing fluid in the ocular implant to exit the implant; and a collection chamber fluidly coupled to the outlet lumen that provides a first fluid outflow resistance and a second fluid outflow resistance. The first fluid outflow resistance is lower than a first resistance to outflow of the implant. The second fluid outflow resistance is greater than a force imparted onto the implant by intraocular pressure of the eye. Injection of therapeutic agent into the implant via the injection lumen causes the pre-existing fluid to exit the implant and enter the collection chamber via the outlet lumen and causes a second pre-existing fluid to displace from the collection chamber.Type: ApplicationFiled: July 13, 2022Publication date: January 5, 2023Inventors: Kevin W. Sacherman, Randolph E. Campbell, Darren Doud, Kathleen Cogan Farinas
-
Patent number: 11432959Abstract: A therapeutic device for extended release drug delivery including a refillable reservoir configured to receive a therapeutic agent and having an outlet for delivery of the therapeutic agent to a patient from the reservoir over an extended period. A porous structure is coupled near the outlet of the reservoir, the porous structure formed of sintered material. A barrier layer is coupled to the reservoir on or adjacent a surface of the porous structure such that the therapeutic agent passes through both the porous structure and the barrier layer upon delivery from the reservoir through the outlet. The porous structure is tuned to deliver the therapeutic agent at a diffusion rate and the barrier layer is adapted to block passage of particles having an average particle size within an average particle size range that is outside an average particle size range blocked by the porous structure. Related methods and systems are provided.Type: GrantFiled: November 18, 2016Date of Patent: September 6, 2022Assignee: ForSight Vision4, Inc.Inventors: Randolph E. Campbell, Kevin W. Sacherman, Kathleen Cogan Farinas, Signe Erickson, Jeremy Boyette
-
Patent number: 11419759Abstract: A device for injecting a therapeutic agent into an ocular implant at least partially implanted in an eye including an injection lumen providing a pathway for injecting the therapeutic agent into the implant; an outlet lumen providing a pathway for pre-existing fluid in the ocular implant to exit the implant; and a collection chamber fluidly coupled to the outlet lumen that provides a first fluid outflow resistance and a second fluid outflow resistance. The first fluid outflow resistance is lower than a first resistance to outflow of the implant. The second fluid outflow resistance is greater than a force imparted onto the implant by intraocular pressure of the eye. Injection of therapeutic agent into the implant via the injection lumen causes the pre-existing fluid to exit the implant and enter the collection chamber via the outlet lumen and causes a second pre-existing fluid to displace from the collection chamber.Type: GrantFiled: May 18, 2020Date of Patent: August 23, 2022Assignee: ForSight Vision4, Inc.Inventors: Kevin W. Sacherman, Randolph E. Campbell, Darren Doud, Kathleen Cogan Farinas
-
Patent number: 11065151Abstract: An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.Type: GrantFiled: December 18, 2020Date of Patent: July 20, 2021Assignee: ForSight Vision4, Inc.Inventors: Eugene de Juan, Jr., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, K. Angela Macfarlane, Cary J. Reich, Randolph E. Campbell, Signe Erickson, Blaine Bueche
-
Publication number: 20210205130Abstract: A therapeutic device for extended release drug delivery including a refillable reservoir configured to receive a therapeutic agent and having an outlet for delivery of the therapeutic agent to a patient from the reservoir over an extended period. A porous structure is coupled near the outlet of the reservoir, the porous structure formed of sintered material. A barrier layer is coupled to the reservoir on or adjacent a surface of the porous structure such that the therapeutic agent passes through both the porous structure and the barrier layer upon delivery from the reservoir through the outlet. The porous structure is tuned to deliver the therapeutic agent at a diffusion rate and the barrier layer is adapted to block passage of particles having an average particle size within an average particle size range that is outside an average particle size range blocked by the porous structure. Related methods and systems are provided.Type: ApplicationFiled: November 18, 2016Publication date: July 8, 2021Applicant: ForSight Vision4, Inc.Inventors: Randolph E. CAMPBELL, Kevin W. SACHERMAN, Kathleen Cogan FARINAS, Signe ERICKSON, Jeremy BOYETTE
-
Publication number: 20210196510Abstract: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the fist side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.Type: ApplicationFiled: September 10, 2020Publication date: July 1, 2021Inventors: Eugene de Juan, JR., Yair Alster, Kathleen Cogan Farinas, K. Angela Macfarlane, Cary J. Reich, Randolph E. Campbell
-
Publication number: 20210113374Abstract: An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.Type: ApplicationFiled: December 18, 2020Publication date: April 22, 2021Inventors: Eugene de Juan, JR., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, K. Angela Macfarlane, Cary J. Reich, Randolph E. Campbell, Signe Erickson, Blaine Bueche
-
Publication number: 20210025885Abstract: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.Type: ApplicationFiled: April 7, 2020Publication date: January 28, 2021Inventors: Eugene de Juan, JR., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, Hanson S. Gifford, III, K. Angela Macfarlane, Cary J. Reich, Michael Barrett, Randolph E. Campbell, Robert George, Douglas Sutton
-
Publication number: 20200405537Abstract: Methods and apparatus provide treatment with a first therapeutic agent and a second therapeutic agent for an extended time. The first therapeutic agent may comprise a VEGF inhibitor and the second therapeutic agent may comprise an antiinflammatory, such as a non-steroidal anti-inflammatory, for example a cyclooxygenase inhibitor. One or more of the first therapeutic agent or the second therapeutic agent can be injected into the eye, for example injected into a therapeutic device implanted into the eye to release the injected therapeutic agent for an extended time.Type: ApplicationFiled: March 4, 2020Publication date: December 31, 2020Inventors: Eugene de Juan, JR., Yair Alster, Kathleen Cogan Farinas, Cary J. Reich, Randolph E. Campbell, K. Angela MacFarlane, Signe Erickson
-
Patent number: 10874548Abstract: An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.Type: GrantFiled: May 26, 2017Date of Patent: December 29, 2020Assignee: ForSight Vision4, Inc.Inventors: Eugene de Juan, Jr., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, K. Angela Macfarlane, Cary J. Reich, Randolph E. Campbell, Signe Erickson, Blaine Bueche
-
Publication number: 20200337897Abstract: A device for injecting a therapeutic agent into an ocular implant at least partially implanted in an eye including an injection lumen providing a pathway for injecting the therapeutic agent into the implant; an outlet lumen providing a pathway for pre-existing fluid in the ocular implant to exit the implant; and a collection chamber fluidly coupled to the outlet lumen that provides a first fluid outflow resistance and a second fluid outflow resistance. The first fluid outflow resistance is lower than a first resistance to outflow of the implant. The second fluid outflow resistance is greater than a force imparted onto the implant by intraocular pressure of the eye. Injection of therapeutic agent into the implant via the injection lumen causes the pre-existing fluid to exit the implant and enter the collection chamber via the outlet lumen and causes a second pre-existing fluid to displace from the collection chamber.Type: ApplicationFiled: May 18, 2020Publication date: October 29, 2020Inventors: Kevin W. Sacherman, Randolph E. Campbell, Darren Doud, Kathleen Cogan Farinas
-
Patent number: 10813788Abstract: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.Type: GrantFiled: June 29, 2015Date of Patent: October 27, 2020Assignee: ForSight Vision4, Inc.Inventors: Eugene de Juan, Jr., Yair Alster, Kathleen Cogan Farinas, K. Angela MacFarlane, Cary J. Reich, Randolph E. Campbell
-
Patent number: 10765677Abstract: The present disclosure relates to stable formulations of receptor tyrosine kinase inhibitors (TKI), e.g., pazopanib; methods of preparation thereof; and use of the disclosed formulations in sustained delivery of the active agent to a target site. The disclosure further relates to methods of converting one polymorphic Form of a TKI to another polymorphic Form and/or an amorphous form.Type: GrantFiled: June 7, 2019Date of Patent: September 8, 2020Assignee: ForSight Vision4, Inc.Inventors: Judit Horvath, Irina Astafieva, Signe Erickson, Kathleen Cogan Farinas
-
Patent number: 10653554Abstract: An injector apparatus comprises an elongate structure having one or more openings positionable near a penetrable barrier of an implantable device so as to receive fluid of the implantable device. The apparatus comprises a needle and a sheath extending over at least a portion of the needle. The elongate structure may comprise a distal tip to penetrate tissue and the penetrable barrier, and a distal opening near the tip to release therapeutic fluid into the implantable chamber. In many embodiments the distal tip, the distal opening, and the plurality of openings are separated from a stop that engages a tissue of the patient and limit penetration depth such that the distal opening and the plurality of openings are located along an axis of the implantable device to increase an efficiency of the exchange.Type: GrantFiled: January 22, 2018Date of Patent: May 19, 2020Assignee: ForSight Vision4, Inc.Inventors: Darren Doud, Randolph E. Campbell, Signe Erickson, K. Angela Macfarlane, Mike Barrett, Christina Skieller, David Batten, Greg Stine, Eugene de Juan, Jr., Douglas Sutton, Kathleen Cogan Farinas
-
Patent number: 10617557Abstract: Methods and apparatus provide treatment with a first therapeutic agent and a second therapeutic agent for an extended time. The first therapeutic agent may comprise a VEGF inhibitor and the second therapeutic agent may comprise an antiinflammatory, such as a non-steroidal anti-inflammatory, for example a cyclooxygenase inhibitor. One or more of the first therapeutic agent or the second therapeutic agent can be injected into the eye, for example injected into a therapeutic device implanted into the eye to release the injected therapeutic agent for an extended time.Type: GrantFiled: August 5, 2011Date of Patent: April 14, 2020Assignee: ForSight Vision4, Inc.Inventors: Eugene de Juan, Yair Alster, Kathleen Cogan Farinas, Cary J. Reich, Randolph E. Campbell, K. Angela MacFarlane, Signe Erickson